HCN Oncology Essentials: Hematologic Malignant Disease | Diffuse Midline Glioma | HER2-Negative BCAugust 24, 2021 | Oncology Hematology Antibody Response to COVID-19 Vaccination in Adults with Hematologic Malignant Disease Publication: JAMA OncologyMethod: Retrospective study of 160 adults with hematologic malignant disease who were vaccinated with 1 of 3 COVID-19 vaccines (February through April 2021).Results: Patients receiving B-cell-depleting immunotherapy may not gain adequate protection from vaccination and may still develop a potentially fatal infection. Read full article Hematology My Beautiful Boy An oncologist pens an essay about his 10-year-old son who died in March 2021 from diffuse midline glioma, providing a glimpse into his own extreme truths about the burden he carries in treating cancer patients. Read full article Internal Medicine The Evolving Use of SERDs in ER+, HER2-Metastatic Breast Cancer This Q&A with Dana Farber’s Dr. Rinath Jeselsohn centers on fulvestrant (Faslodex, AZ) and its current role in the management of breast cancer, as well as outlining the emerging selective estrogen receptor degraders (SERDs), their clinical trial data, potential for use, and whether the options will become the “backbone” of endocrine therapy in HER2-negative metastatic breast cancer. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS